AbCellera is celebrating a double win: the company has been named on Fast Company’s prestigious annual list of Best Workplaces for Innovators. Additionally, AbCellera has been awarded the Innovative Team of the Year.
Fast Company recognized AbCellera for its one-of-a-kind drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs. By innovating at every step of the discovery process, AbCellera has repeatedly proven its ability to unlock novel targets, including those previously considered ‘undruggable’ due to technical challenges associated with antibody generation.
AbCellera’s Pandemic Prevention Platform (P3) team has received the honor of Innovative Team of the Year for its efforts in developing antibody countermeasures against COVID-19. Antibodies are one of the most promising therapeutic approaches for easing the COVID-19 crisis. The challenge is finding the best antibodies to block infection and quickly. The P3 team has led the global search for human antibodies against the virus that causes COVID-19 with unprecedented throughput and speed.
In just 11 days, AbCellera screened millions of single cells from a recovered patient, identified hundreds of antibodies targeting SARS-CoV-2, moved into functional testing with global virology experts, and signed an antibody-drug co-development agreement with Eli Lilly and Company to get a new antibody-based medicine to patients in need. The investigational medicine LY-CoV555 that emerged from these discovery efforts was used in the world’s first study of potential antibody treatments for COVID-19 in humans.